期刊文献+

不同疗程1%卢立康唑乳膏治疗足癣的多中心、随机双盲对照研究 被引量:16

Comparison of 2 weeks versus 4 weeks of luliconazole 1% cream for the treatment of tinea pedis: a randomized, double-blind, multicenter, controlled trial
原文传递
导出
摘要 目的观察和评价不同疗程1%卢立康唑乳膏治疗足癣的疗效和安全性。方法采用多中心、随机、双盲、阳性药物对照研究,将入选患者按照试验中心分层随机分成3组,包括卢立康唑短疗程组(外用l%卢立康唑乳膏,每日1次,共2周,后2周使用安慰剂)、卢立康唑长疗程组(外用1%卢立康唑乳膏,每日1次,共4周)、联苯苄唑对照组(外用1%联苯苄唑乳膏,每日1次,共4周)。开始用药后第2、3、4、6周评价临床和真菌学疗效。结果420例真菌镜检阳性的患者随机分成3组,每组140例,398例患者进入疗效分析。用药2周时,对照组、短疗程组、长疗程组临床有效率分别为29.29%、31.43%和35.00%(P〉0.05),真菌清除率分别为49.29%、58.57%和57.86%(P〉0.05);用药3周时,临床有效率分别为73.57%、78.57%和70.00%(P〉0.05);用药4周时,临床有效率分别为89.29%、91.43%和89.29%(P〉0.05),真菌清除率分别为80.00%、87.86%和85.00%(P〉0.05)。停药后2周,对照组、短疗程组、长疗程组的临床有效率分别是92.14%、92.86%和92.14%(P〉0.05),真菌清除率分别为80.71%、90.00%和89.29%(P〈o.05)。对照组局部不良反应发生率为o.71%,短疗程组为o,长疗程组为2.14%。结论1%卢立康唑乳膏外用治疗足癣安全有效,每日1次治疗2周与治疗4周的疗效相当。 Objective To evaluate the efficacy and safety of different courses of luliconazole 1% cream in the treatment of tinea pedis. Methods A randomized, double-blind, multicenter controlled trial was conducted. According to a stratified randomization protocol, 420 patients positive for fungal elements on direct microscopy were equally and randomly divided into 3 groups: short-term group applying luliconazole 1% cream once daily for 2 weeks followed by placebo once daily for the next 2 weeks, long-term group applying luliconazole 1% cream once daily for 4 weeks, bifonazole group applying bifonazole 1% cream once daily for 4 weeks. Efficacy was assessed in terms of mycological clearance and clinical response rates on week 2, 3, 4 and 6 after initiation of treatment. Statistical analysis was carried out by paired t test, analysis of variance, chi-square test and a nonparametric test. Results Finally, 398 patients were eligible for the efficacy analysis. The clinical response rate in the bifonazole group, short- term group and long-term group was 29.29%, 31.43% and 35.00% respectively on week 2 after initiation of treatment (P 〉 0.05), 73.57%, 78.57% and 70.00% respectively on week 3 (P 〉 0.05), 89.29%, 91.43% and 89.29% respectively on week 4 (P 〉 0.05), with the mycological clearance rate being 49.29%, 58.57% and 57.86% respectively on week 2 (P 〉 0.05), 80.00%, 87.86% and 85.00% respectively on week 4 (P 〉 0.05). Significant differences were observed on week 2 after the end of treatment in mycological clearance rate (80.71% in the bifonazole group vs. 90.00% in the short-term group vs. 89.29% in the long-term group, P 〈 0.05), but not in clinical response rate (92.14% in the bifonazole group vs. 92.86% in the short-term group vs. 92.14% in the long- term group, P 〉 0.05). The incidence rate of local adverse reactions was 0.71% in the bifonazole group, 0 in the short-term group and 2.14% in the long-term group. Conclusion Luliconazole 1% cream is effective and well tolerated in the treatment of tinea pedis, with the efficacy of 2-week once-daily regimen equivalent to that of 4-week once-daily regimen.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2014年第7期453-456,共4页 Chinese Journal of Dermatology
关键词 卢立康唑 联苯苄唑 临床方案 随机对照试验 Luliconazole Bilonazole Tinea, pedis Clinical protocols Randomized controlled trials
  • 相关文献

参考文献13

  • 1Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition [J]. Br J Dennatol, 1992, 126 Suppl 39: 2-7.
  • 2Sud IJ, Feingold DS. Mechanisms of action of the antimycotic imidazoles[J]. J Invest Dennatol, 1981,76(6): 438-441.
  • 3Saito R, Sawada M, Ishizaki S, et al. A case of inflammatory tinea corporis by Epidennophyton l1occosum [J]. Nihon Ishinkin Gakkai Zasshi, 2008, 49(3): 211-215.
  • 4Katoh T. Guidelines for diagnosis and treatment of mucocutaneous candidiasis [J]. Nihon Ishinkin Gakkai Zasshi, 2009, 50 (4): 207-212.
  • 5Uchida K, Nishiyama Y, Tanaka T, et al. In vitro activity of novel imidazole antifungal agent NND-502 against MaIassezia species [J]. Int J Antimicrob Agents, 2003, 21( 3): 234-238.
  • 6Padhye AA, Weitzman I. The dennatophytesllAjello L, Hay RJ. Topley & Wilson's microbiology and microbial infections, volume 4: medical mycology [M]. 9th ed. London: Arnold, 1998: 215- 236.
  • 7Koga H, Nanjoh Y, Kaneda H, et al. Short-term therapy with luliconazole, a novel topical antifungal imidazole, in guinea pig models of tinea corporis and tinea pedis [J]. Antimicrob Agents Chemother, 2012, 56(6): 3138-3143.
  • 8Ghannoum MA, Long L, Kim HG, et al. Efficacy of terbinafine compared to lanoconazole and luliconazole in the topical treatment of dermatophytosis in a guinea pig model [J]. Med Mycol, 2010, 48(3): 491-497.
  • 9Watanabe S, Takabashi H, Nishikawa T, et al. Dose-finding comparative study of 2 weeks of luliconazole cream treatment for tinea pedis-comparison between three groups (1 %, 0.5%, 0.1 %) by a multi-center randomized double-blind study [J]. Mycoses, 2007,50(1): 35-40.
  • 10Watanabe S, Takabashi H, Nishikawa T, et aI. A comparative clinical study between 2 weeks of luliconazole 1 % cream treatment and 2 weeks of bifonazole 1 % cream treatment for tinea pedis[J]. Mycoses, 2006, 49(3): 236-241.

二级参考文献13

  • 1Koga H, Nanjoh Y, Makimura K, et al. In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol, 2009, 47(6): 640-647.
  • 2Watanabe S, Takahashi H, Nishikawa T, et al. Dose-finding comparative study of 2 weeks of luliconazole cream treatment for tinea pedis-comparison between three groups (1%, 0.5%, 0.1%) by a multi-center randomised double-blind study. Mycoses, 2007, 50( 1 ): 35-40.
  • 3Watanabe S, Takahashi H, Nishikawa T, et al. A comparative clinical study between 2 weeks of luliconazole 1% cream treatment and 4 weeks of bifonazole 1% cream treatment for tinea pedis. Mycoses, 2006, 49(3): 236-241.
  • 4Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard CLSI document M27-A3. Wayne, PA. 2008.
  • 5Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Third Infor- mational Supplement. CLSI Document M27-$3. Wayne, PA, 2008.
  • 6Uehida K, Tanaka T, Yamaguchi H. Achievement of complete mycol- ogical cure by topical antifungal agent NND-502 in guinea pig model of tinea pedis. Microbiol Immunol, 2003, 47(2): 143-146.
  • 7Niwano Y, Kuzuhara N, Goto Y, et al. Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida alblcans and Aspergillus fumlgatus infections. Int J Antimicrob Agents, 1999, 12(3): 221-228.
  • 8Uchida K, Nishiyama Y, Tanaka T, et al. In vitro activity of novel imidazole antifungal agent NND-502 against Malassezia species. Int J Antimicrob Agents, 2003, 21(3): 234-238.
  • 9Koga H, Tsuji Y, Inoue K, et al. In vitro antifungal activity of luliconazole against clinical isolates from patients with dermato- mycoses. J Infect Chemother, 2006, 12(3): 163-165.
  • 10Uchida K, Nishiyama Y, Yamaguchi H. In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother, 2004, 10(4): 216-219.

共引文献5

同被引文献66

引证文献16

二级引证文献107

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部